Clinical Trial

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-07-23; most recent amendment 2026-05-11.
Trial Details
NCT Number NCT07085091
Lead Sponsor ALX Oncology Inc.
Conditions NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC)
Enrollment 170 participants
Start Date 2025-08-18
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-12